Business Wire

Morgan Stanley Investment Management Launches ESG Strategies Across Europe Managed by Calvert Research and Management

4.5.2022 10:30:00 EEST | Business Wire | Press release

Share

Calvert Research and Management (Calvert), a subsidiary of Morgan Stanley Investment Management, today announced the European launch of a suite of responsible investing strategies focused on Environmental, Social and Governance (ESG) factors. The new Calvert strategies meet the SFDR Article 9 criteria and have a sustainable investment objective across the ESG spectrum. This news follows MSIM’s acquisition of Eaton Vance, Calvert’s parent company in March, 2021.

Calvert, a recognized pioneer and leader in responsible investing since 1982, employs proprietary fundamental research, financially material ESG data analysis and direct company engagement to deliver competitive investment results across asset classes. The newly available strategies form a robust suite of offerings that invest in companies with leading ESG characteristics with the core objective of long-term value creation and positive global impact.

The Calvert Article 9 Funds are available through Morgan Stanley Investment Management’s distribution network and include the following:

  • MSINVF Calvert Sustainable Developed Europe Equity Select Fund
  • MSINVF Calvert Sustainable Developed Markets Equity Select Fund
  • MSINVF Calvert Sustainable Emerging Markets Equity Select Fund *
  • MSINVF Calvert Sustainable US Equity Select Fund
  • MSINVF Calvert Sustainable Diversity, Equity and Inclusion Fund
  • MSINVF Calvert Sustainable Climate Aligned Fund

“We are excited about leveraging Morgan Stanley Investment Management’s leading non-U.S. distribution capabilities to bring Calvert’s proven, Principles-based sustainable investment strategies to a much broader universe of investors,” said John Streur, President and Chief Executive Officer of Calvert Research and Management. “Our proprietary research system drives our investment process and enables us to identify the companies leading their peers in managing financially material ESG risks and opportunities, and those that are positioned for longer-term success and improved societal outcomes.”

Promoting environmental sustainability and resource efficiency, advocating for equitable societies and enhanced societal outcomes as well as demanding accountable governance and transparent operations are the core of the Calvert Principles for Responsible Investment, which form the foundation of Calvert’s investment process.

Calvert is a signatory to, and has played a leading role in spearheading, a number of global initiatives such as the United Nations Environment Programme Finance Initiative’s Principles of Responsible Investing (PRI), the Women’s Empowerment Principles and the UN Global Compact. Calvert also partners extensively with leading academic institutions and other ESG-oriented organizations to promote industry leading collaborative research.

“The combination of our research and engagement processes plus our work to support global change initiatives position us to offer impact-driven, responsible investing strategies that deliver long-term shareholder value and drive positive change,” added Mr. Streur.

“We are delighted to be able to bring Calvert’s historic understanding of ESG analysis, knowledge of responsible investing and success in long-term value creation to our European clients,” said Jacques Chappuis, Global Head of Distribution and Co-Head of the Solutions and Multi-Asset Group at Morgan Stanley Investment Management.. “Investors are increasingly focused on sustainability, and the launch of these new funds demonstrates our focus on delivering our clients best-in-class and market-leading products and solutions that align investor values with financial outcomes. European investors have a sophisticated understanding of how sustainability factors can lead to business success and Calvert has been honing this process for 40 years.”

* This fund is approved and will be available in the coming weeks

About Calvert Research and Management

Calvert Research and Management is a global leader in responsible investing. Calvert sponsors one of the largest and most diversified families of responsibly invested mutual funds, encompassing active and passively managed equity, income, alternative and multi-asset strategies, with approximately $37.3 billion in assets under management as of March 31, 2022.

With roots in responsible investing dating back to the 1982 launch of the first mutual fund to oppose investing in companies doing business in apartheid-era South Africa, the firm seeks to generate favourable investment returns for clients by allocating capital consistent with environmental, social and governance best practices and through structured engagement with portfolio companies. Headquartered in Washington, D.C., Calvert manages assets on behalf of funds, individual and institutional separate account clients, and their advisors. Calvert Research and Management is a wholly owned subsidiary of Morgan Stanley Investment Management.

About Morgan Stanley Investment Management

Morgan Stanley Investment Management, together with its investment advisory affiliates, has more than 767 investment professionals around the world and $1.4 trillion in assets under management or supervision as of March 31, 2022. Morgan Stanley Investment Management strives to provide outstanding long-term investment performance, service and a comprehensive suite of investment management solutions to a diverse client base, which includes governments, institutions, corporations and individuals worldwide. For further information about Morgan Stanley Investment Management, please visit www.morganstanley.com/im.

About Morgan Stanley

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 41 countries, the Firm's employees serve clients worldwide including corporations, governments, institutions and individuals. For more information about Morgan Stanley, please visit www.morganstanley.com.

Disclaimer:

FMIL

This marketing communication has been issued by Morgan Stanley Investment Management Fund Management (Ireland) Limited. Morgan Stanley Investment Management Fund Management (Ireland) Limited is regulated by the Central Bank of Ireland. Morgan Stanley Investment Management Fund Management (Ireland) Limited is incorporated in Ireland as a private company limited by shares with company registration number 616661 and has its registered address at The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42, Ireland.

MSINVF CBDF

This is a marketing communication. Applications for shares in the Fund should not be made without first consulting the current Prospectus and the Key Investor Information Document (“KIID”), which are available in English and in the official language of your local jurisdiction at morganstanleyinvestmentfunds.com or free of charge from the Registered Office of Morgan Stanley Investment Funds, European Bank and Business Centre, 6B route de Trèves, L-2633 Senningerberg, R.C.S. Luxemburg B 29 192. A summary of investor rights is available in English at the same website.

If the management company of the relevant Fund decides to terminate its arrangement for marketing that Fund in any EEA country where it is registered for sale, it will do so in accordance with the relevant UCITS rules.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Tom Walton
Tom.Walton@morganstanley.com

Colleen McElhinney
Colleen.McElhinney@morganstanley.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye